Diagnostica Stago SAS - proposed acquisition of Trinity Biotech's haemostasis business

Status: 
Completed
Outcome: 
Not opposed on 1 April 2010
Reference number: 
40957
Industry: 
Haemostasis reagents and instruments
Commenced: 
15 March 2010
Total review days: 
14 days

Acquirer(s)

  • Diagnostica Stago SAS

Target(s)

  • Trinity Biotech's haemostasis business

Summary

Diagnostica Stago SAS - proposed acquisition of Trinity Biotech's haemostasis business

Market definition

It was not considered necessary to form a definitive view on the relevant market definition. However, the acquisition was considered in relation to the Australian market for haemostasis reagents and instruments.

Competition analysis

It was considered that the proposed acquisition would be unlikely to result in a substantial lessening of competition in any market, including because it appears:

- the merged firm is likely to continue to face strong competition from substitute suppliers, notably Siemens Healthcare Diagnostics and Beckman Coulter; and

- the proposed acquisition is unlikely to result in the removal of a vigorous and effective competitor.

Timeline

DateEvent
15/03/2010ACCC commenced a review under the Merger Review Process Guidelines.
26/03/2010Closing date for submissions from interested parties.
01/04/2010ACCC announced it would not oppose the proposed acquisition.